Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pavel Jindra.
Journal of Cutaneous Pathology | 2006
Ludmila Boudova; Dmitry V. Kazakov; Pavel Jindra; Radek Sima; Tomas Vanecek; Vilem Kuntscher; Vozobulova Vera; Jiri Bouda; Michal Michal
Background: Cutaneous lymphomas co‐expressing CD56 and CD30 are very rare. They share a clinicopathological overlap with natural killer‐ (NK)/T‐cell lymphomas and anaplastic large‐cell lymphomas (ALCLs), two entities with widely disparate clinical behavior.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia | 2013
Daniel Lysák; Tomas Vlas; Monika Holubová; Michaela Miklikova; Pavel Jindra
AIMS Mesenchymal stromal cells (MSC) derived from adult bone marrow or adipose tissue offer the potential to open a new frontier in medicine. MSC are involved in modulating immune response and tissue repair in vitro and in vivo. Experimental evidence and preliminary clinical studies have demonstrated that MSC exhibit an important immunomodulatory function in patients with graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. The immunosuppressive properties of MSC have already been exploited in the clinical setting. However the precise mechanisms are being still investigated. METHODS We examined the immunosuppressive function of MSC by coculturing them with stimulated HLA incompatible allogeneic lymphocytes in a mixed lymphocyte culture test. The metabolic and proliferative activity of lymphocytes was determined by MTT test. RESULTS After stimulation with alloantigens the presence of MSC caused significant decrease of absorbance levels by 62% (P<0.01), 26% (P<0.01) and 6% (P=0.0437) in comparison to positive control depending on the MSC/lymphocyte ratio (1:5, 1:50, 1:500). The mitogenic stimulation of lymphocytes with fMLP or PHA was also significantly reduced during MSC cocultivation. The absorbance was reduced by 42% (P<0.001) and 67% (P<0.001). CONCLUSIONS Allogeneic bone marrow is an ideal source of MSC for clinical application. The experiments confirmed the dose-dependent inhibitory effect of MSC on lymphocyte proliferation triggered by cellular or mitogenic stimulation. The mixed lymphocyte culture test offers a simple method for characterization and verification of the immunosuppressive potential of MSC, being prepared for clinical use.
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti | 2013
Samuel Vokurka; Radek Tupý; Ludmila Boudova; Jan Mraček; Pavel Jindra; Jiří Ferda; Marcela Hrabětová
Medicína pro praxi | 2018
Kateřina Steinerová; Daniel Lysák; Pavel Jindra
Transfuze a hematologie dnes | 2016
Pavel Jindra; Michal Karas; Tomáš Szotkowski; Daniel Lysák; Luděk Raida; Alexandra Jungová; Adam Kuba; Marcela Hrabětová; C Martin; Kateřina Steinerová
Archive | 2016
Alexandra Jungová; Samuel Vokurka; Miroslava Schützová; Lekaa Mohammadova; Kateřina Steinerová; Daniel Lysák; Pavel Jindra; Michal Karas
Archive | 2016
Kateřina Steinerová; Daniel Lysák; Michal Karas; Marcela Hrabětová; Pavel Jindra
Archive | 2016
Michal Karas; Kateřina Steinerová; Daniel Lysák; Marcela Hrabětová; Alexandra Jungová; Pavel Jindra
Klinická onkologie | 2016
Samuel Vokurka; Mha MUDr. Jindřich Fínek; Tomáš Svoboda; Radovan Vojtíšek; Marie Votavová; Karel Havránek; Jiří Salvét; Blanka Šindelářová; Jan Mařan; Emília Sukovská; Krasimir Vasilev; Miroslava Schützová; Věra Vozobulová; Pavel Jindra; Josef Sýkora
Archive | 2015
Lekaa Mohammadova; Pavel Jindra; Kateřina Steinerová